Mycobacterium tuberculosis: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Alex Lee
imported>Alex Lee
Line 117: Line 117:
- Interference with oxygen intermediates
- Interference with oxygen intermediates


==Application to Biotechnology==
 
Does this organism produce any useful compounds or enzymes?  What are they and how are they used?


==Current Research==
==Current Research==

Revision as of 17:34, 18 April 2008

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Attention niels epting.png
Attention niels epting.png
This article is currently being developed as part of an Eduzendium student project. If you are not involved with this project, please refrain from collaboratively developing it until this notice is removed.
Articles that lack this notice, including many Eduzendium ones, welcome your collaboration!


TB Culture.jpg
Scientific classification
Kingdom: Bacteria
Phylum: Actinobacteria
Class: Actinomycetales
Order: Corynebacterineae
Family: Mycobacteriaceae
Genus: Mycobacterium
Species: tuberculosis
Binomial name
Mycobacterium tuberculosis

Description and significance

Mycobacterium tuberculosis was first isolated and described in 1882 by Dr. Robert Koch, who later went on to win the Nobel Prize in 1905 for his discovery. Also known as, "Tubercle Bacillus", and Koch's bacillus, M. Tuberculosis is a non-motile, rod shaped bacterium, and the primary cause for the widespread disease tuberculosis.

The World Health Organization estimates that one-third of the world's population is infected with M. Tuberculosis, and that someone new is infected every second. [1] With the emergence of drug resistant strains, both multi drug resistant (MDR) and extensively drug resistant (XDR), controlling the spread of tuberculosis has become a major concern. Since 2006, the WHO's primary strategy in its Stop TB Strategy has been the use of DOTS (Directly Observed Treatment, Short-course). It is estimated to be the most cost effective strategy, only costing $3-$7 to gain a year of health. [2]

Genome structure

The genome for two strains of M. Tuberculosis have been sequenced completely. In 1998, the Sanger Institute sequenced the common laboratory strain, H37rv. At the same time, strain CD1551 was sequenced by The Institute for Genomic Research (TIGR) using the whole genome random sequencing method (shotgun sequencing). The CDC-1551 strain has been shown to be more virulent than the H37rv strain. By comparing both genomes, key information can be obtained about the virulence, survivability (drug resistance), and evolution of M. Tuberculosis. [3][4]

Chart from "TIGR"summarizing the CDC-1551 strain

DNA Molecule Summary
Total Number of all DNA molecules: 1 100.00%
Total Size of all DNA molecules: 4403837 bp 100.00%
Number of Primary Annotation coding bases: 4069477 bp 92.40%
Number of G+C bases: 2889216 bp 65.60%
Primary Annotation Summary
Total genes: 4294 100.00%
Protein coding genes: 4246 98.88%
Genes assigned a role category: 2317 54.56%
Genes not assigned a role category: 2 0.04%
Conserved hypothetical genes: 655 15.42%
Hypothetical genes: 1272 29.95%
tRNA genes: 45 1.04%
rRNA genes: 3 0.06%

Cell structure and metabolism

M. Tuberculosis: Ziehl-Neelsan Stain

M. Tuberculosis is a non-motile, rod shaped bacterium roughly 2-4 um in length and 0.2-0.5 um in width. It's an obligate aerobe and neither gram positive or negative. Although it has a peptidoglycan layer, M. Tuberculosis does not retain the crystal violet dye. To solve this issue, acid-fast staining is used (specifically Ziehl-Neelsan Stain). The peptidoglycan layer is of particular interest. It is composed mostly of lipids (60%). The high lipid percentage (lipids: Mycolic Acid, Cord Factor, Wax-D) is the likely cause of the high survivability of M. Tuberculosis. Factors include: impermeability to stains; resistance to antibiotics, osmotic lysis, acidic and alkaline compounds, and protection from oxygen free radicals. other factors that add to the survivability of M. Tuberculosis include the ability to grow intracellularly within macrophages (exact reason is unknown), and it's slow rate of growth compared to other bacteria (about 15-20 hours). The slow rate of growth may deter it's detection by the immune system.[5]



Ecology

Chest X-ray of lungs showing M. Tuberculosis

M. Tuberculosis generally resides in the lungs where oxygen is more readily available. However, if the bacteria enters the blood stream, or lymphatic system, it can spread throughout the body and infect various other organs (brain, kidney, liver, etc.) When this happens, it is known as miliary tuberculosis.

M. Tuberculosis has an increased capability to survive outside our system due to its highly lipid based peptidoglycan layer. Within our system, M. Tuberculosis are consumed by macrophages, however lysosome-phagosome fusion is prevented, and M. TB is able to grow inside the macrophages.[6][7]

Pathology

(Temporary General Outline)

- Major cause of tuberculosis (can link to tuberculosis page later)

- Binding to mannose receptors (for entry into cell)

- Ability to prevent lysosome from fusing with phagosome, as a result prevents the destruction of the bacteria.

- Slow generation may actually help the bacteria from being detected by the immune system.

- Cell wall construction is 60% lipid. Lot of different types of resistances.

- Antigen 85: binds to fibronectin and may help in protecting the bacteria from the immune system.

- Interference with oxygen intermediates


Current Research

Summaries to come

Pubmed article about BCG vaccine

Pubmed article about the discovery of lipolytic enzymes which may be involved with virulence

Article concering multi-drug resistant mycobacterium tuberculosis

References

1. www.textbookofbacteriology.net

2. Honaker RW, Stewart A, Schittone S, Izzo A, Klein MR, Voskuil MI "BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy." Infect Immun. 2008 Mar 24

3. Côtes K, Bakala N'goma JC, Dhouib R, Douchet I, Maurin D, Carrière F, Canaan S. "Lipolytic enzymes in Mycobacterium tuberculosis." Appl Microbiol Biotechnol. 2008 Apr;78(5):741-749. Epub 2008 Feb 29.

4. Raphael C. Y. Chan, Mamie Hui, Edward W. C. Chan, T. K. Au, Miu L. Chin, Chun K. Yip1, Carrie K. W. AuYeang, Christina Y. L. Yeung1, Kai M. Kam, Peter C. W. Yip and Augustine F. B. Cheng. "Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong" Journal of Antimicrobial Chemotherapy 2007 59(5):866-873.